Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension

被引：0

作者：

Thaci, Diamant ^{[1
]}

Puig, Luis ^{[2
]}

Merola, Joseph F. ^{[3
]}

Jullien, Denis ^{[4
]}

Costanzo, Antonio ^{[5
]}

Wang, Maggie ^{[6
]}

Deherder, Delphine ^{[7
]}

Lopez Pinto, Jose M. ^{[8
]}

Lebwohl, Mark ^{[9
]}

机构：

[1] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Schleswig Holst, Germany

[2] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain

[3] UT Southwestern Med Ctr, Dallas, TX USA

[4] Univ Lyon, Hosp Civils Lyon, Dept Dermatol, Hop Edouard Herriot, Lyon, France

[5] IRCCS, Dept Dermatol, Humanitas Clin & Res Ctr, Milan, Italy

[6] UCB Pharma, Morrisville, NC USA

[7] UCB Pharma, Braine Lalleud, Belgium

[8] UCB Pharma, Madrid, Spain

[9] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2024年 / 76卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2348

引用

页码：4733 / 4735

页数：3

共 3 条

[1] Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial [J].

Strober, Bruce ;

Tada, Yayoi ;

Mrowietz, Ulrich ;

Lebwohl, Mark ;

Foley, Peter ;

Langley, Richard G. ;

Warren, Richard B. ;

Wang, Maggie ;

Vanvoorden, Veerle ;

Szilagyi, Balint ;

Ciaravino, Valerie ;

Paul, Carle .

BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (06) :749-759

[2]

Thaci D, PRESENTED AT EADV 20

[3] Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial [J].

Thaci, Diamant ;

Vender, Ron ;

de Rie, Menno A. ;

Conrad, Curdin ;

Pariser, David M. ;

Strober, Bruce ;

Vanvoorden, Veerle ;

Wang, Maggie ;

Madden, Cynthia ;

de Cuyper, Dirk ;

Kimball, Alexa B. .

BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (01) :22-31

← 1 →